Obeldesivir

Summary

Obeldesivir (CHEMBL4863829) is a phase-3 clinical-stage small molecule; indicated across 1 condition including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 361.35 Da · C16H19N5O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4863829
Name	Obeldesivir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	162513664
Molecular formula	C16H19N5O5
Molecular weight	361.35
InChIKey	YIHPGVCWGSURHO-VSBTWAGUSA-N

SMILES: CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O

IUPAC name: [(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl 2-methylpropanoate

Also known as: ATV-006, ATV006, GS-5245, Obeldesivir, OBELDESIVIR

Patent coverage: 11 distinct patent families (27 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CoV RNA-dependent RNA polymerase	Inhibition

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05603143	PHASE3	TERMINATED	Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
NCT05715528	PHASE3	COMPLETED	Study of Obeldesivir in Nonhospitalized Participants With COVID-19
NCT05996744	PHASE2/PHASE3	TERMINATED	Study of Obeldesivir in Children and Adolescents With COVID-19
NCT06585150	PHASE2	TERMINATED	Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
NCT06682234	PHASE2	WITHDRAWN	Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease
NCT06784973	PHASE2	TERMINATED	Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).